Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-4066
      • ALG.APV-527
      • HLX22
    • Scientific publications
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Corporate deck
    • Capital raisings
      • Preferential Rights Issue Q4 2025
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
  3. Other Corporate Information
Key downloads
Alligator Bioscience publishes Annual Report for 2025Alligator Bioscience AB reports full year financial results for 2025 and for Q4 2025 and provides a business updateBulletin from the extraordinary general meeting in Alligator Bioscience ABAlligator Bioscience AB reports financial results for Q3 2025 and provides a business updateAlligator Bioscience AB reports financial results for Q2 2025 and provides a business update
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRMARRegulatoryReport
View as grid View as list
2024-02-082024-03-21
Regulatory

Alligator carries out a rights issue of units of approximately SEK 150.9 million with an over-allotment issue of up to an additional approximately SEK 100.0 million and raises bridge loans

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Continue reading
2024-01-292024-02-14
Regulatory

Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer

Top-line readout demonstrates Objective Response Rate of 40.4%, meeting primary endpoint and confirming the benefit of mitazalimab in combin ...
Continue reading
2024-01-16

Alligator Bioscience Granted First U.S. Patent for Neo-X-Prime™ Bispecific Antibody ATOR-4066 for Cancer Treatment

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the United States Patent and Trademark Office (USPT ...
Continue reading
2023-10-12

Alligator Bioscience Granted New Composition of Matter Patent in Europe for Mitazalimab

New patent expands protection for mitazalimab in Europe Patent protects composition of matter for mitazalimab until 2038 (including potentia ...
Continue reading
2023-10-05

Alligator Bioscience Announces Publication Highlighting ATOR-1017 Preclinical Data in the Scientific Journal “Cancer Immunology, Immunotherapy”

ATOR-1017, a potential best-in-class 4-1BB monoclonal antibody, demonstrates an excellent preclinical profile with a unique binding site on ...
Continue reading
2023-09-28

Alligator Bioscience Presents New Data Demonstrating Durable Response and Encouraging Anti-Tumor Activity of Lead Asset Mitazalimab

Clinical and preclinical data from three presentations further demonstrate mitazalimab's ability to activate the immune system and enha ...
Continue reading
2023-09-27

Alligator Bioscience Announces Publication Highlighting Pharmacodynamic Data from Mitazalimab Phase 1 Study in Scientific Journal “Cells”

Data demonstrate that mitazalimab induces transcriptomic alterations consistent with immune activation Data reinforce mitazalimab's mod ...
Continue reading
2023-08-21
Regulatory

Alligator Bioscience Receives European Medicine Agency Orphan Designation for Mitazalimab in Pancreatic Cancer

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Medicines Agency (EMA) has granted Orphan De ...
Continue reading
2023-08-17

The exercise period for Alligator’s warrants of series TO 6 begins today

Today, on August 17, 2023, the exercise period for warrants series TO 6 in Alligator Bioscience AB (publ) ("Alligator" or the  ...
Continue reading

Posts navigation

Older posts
Newer posts
  1. Startpage
  2. News
  3. Other Corporate Information
About Alligator

Alligator, a clinical-stage biotechnology company, develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
  • Glossary
Contact us

Headquarter
Alligator Bioscience AB
Medicon Village
Scheeletorget 1
SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2024 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all